Full-Time

Director – Quantitative Pharmacology and Pharmacometrics

Immune/Oncology

Posted on 1/25/2025

Merck

Merck

10,001+ employees

Develops medicines and vaccines for health issues

Compensation Overview

$187k - $294.4kAnnually

+ Bonus Eligibility + Long Term Incentive

Senior, Expert

H1B Sponsorship Available

Remote in USA

This remote position is only applicable for those that are not within commutable distance to primary sites noted in posting. Standard commute is less than 50 miles.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
R
MATLAB
Data Analysis
Requirements
  • Ph.D. with at least seven years of pharmaceutical drug development experience relating to: PKPD, pharmacometrics, mathematics, statistics/biostatistics, or chemical/biomedical engineering.
  • Masters or PharmD, with at least nine years of experience, where 'experience' means having a record of increasing responsibility and independence in a similar role in pharmaceutical drug development.
  • Demonstrated impact with applications of pharmacometrics methods.
  • Experience in IND, NDA and other submissions to global regulatory agencies.
  • Skills in experimental design, mathematical problem solving, critical data analysis/interpretation, and statistics.
  • An exemplary record of increasing responsibility, independence, and demonstrated impact in driving drug development decisions through application of model-based approaches.
  • Proficiency in R, NONMEM, MATLAB, Monolix or other modeling software.
  • Professional working proficiency in written and verbal communication.
Responsibilities
  • Serving as an expert representative for QP2 -IO on Oncology development teams.
  • Framing critical questions and strategy for optimizing model-based analyses on programs.
  • Developing and executing model-based analyses including translational PK/PD approaches, population pharmacokinetic models, exposure-response models, clinical trial design simulation, disease progression models, quantitative systems pharmacology (QSP) modeling, and comparator modeling.
  • Strategizing and executing modeling of tumor size and survival.
  • Maintaining a comprehensive understanding of global regulatory expectations for small molecules and biologics in Oncology, authoring regulatory documents (investigational new drugs/INDs, clinical study reports (CSRs), clinical trial applications (CTDs), and representing QP2-IO at regulatory meetings.
  • Mentoring and/or supervising junior staff to perform the above duties and to develop the above capabilities.
Desired Qualifications
  • Business Intelligence (BI)
  • Database Design
  • Data Engineering
  • Data Modeling
  • Data Science
  • Data Visualization
  • Machine Learning
  • Software Development
  • Stakeholder Relationship Management
  • Waterfall Model

Merck develops medicines and vaccines to address significant health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck's products include prescription medicines, vaccines, and animal health products, which are sold to patients, healthcare professionals, and institutions around the world. A key aspect of Merck's approach is its commitment to patient assistance programs that provide free medicines and vaccines to those in need. Unlike many competitors, Merck also offers professional resources through platforms like Merck Connect and Merck Manuals, enhancing support for healthcare providers. The company's goal is to improve global health by following scientific advancements to develop effective healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Total Funding

$347.4M

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's mRNA technology shows promise for rapid vaccine development.
  • Digital health platforms enhance patient engagement and treatment adherence.
  • Collaborations with tech companies boost Merck's R&D efficiency.

What critics are saying

  • Class action lawsuit could damage Merck's reputation and finances.
  • $900 million Delaware facility investment poses financial risk if returns falter.
  • External research collaborations may lead to intellectual property disputes.

What makes Merck unique

  • Merck's Keytruda leads in personalized oncology immunotherapy treatments.
  • Merck integrates AI in drug discovery, reducing R&D timelines.
  • Merck's animal health division benefits from rising pet ownership and livestock health awareness.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

Delaware Online
Mar 6th, 2025
Delaware approves $30.2 million taxpayer-funded grant for Merck to build in state

Pharmaceutical giant Merck received a $30.2 million grant from the state in an effort to sway the company to build its $900 million manufacturing facility in the Wilmington area.

DNR Online
Mar 5th, 2025
Elkton computer store willing to tackle any technology glitch that arises

When Comer retired from Merck, he worked for Harrisonburg City Public Schools as a tech specialist for eight years.

Slater Sentinel
Mar 2nd, 2025
Hickory Point Bank & Trust Makes New Investment in Merck & Co., Inc. (NYSE:MRK)

Hickory Point Bank & Trust makes new investment in Merck & Co., Inc. (NYSE:MRK).

Investing Snacks
Feb 28th, 2025
BankPlus Trust Makes $601K Investment in Merck

BankPlus Trust makes $601K investment in Merck.

Stockhouse
Feb 28th, 2025
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc.(MRK) of a Class Action Lawsuit and an Upcoming Deadline

THE LAWSUIT: A class action securities lawsuit was filed against Merck & Co., Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025.

INACTIVE